Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients

American Journal of Nephrology

Volumn 28, Issue 2, 2008, Pages 275-279

  Shantouf, Ronney ^a   Budoff, Matthew J ^a,b   Ahmadi, Naser ^a   Tiano, Jima ^a   Flores, Ferdinand ^a   Kalantar Zadeh, Kamyar ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiac computed tomography; Coronary calcium; End stage renal disease; Phosphate binders

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTERY CALCIFICATION; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY; DEMOGRAPHY; DISEASE COURSE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; NUTRITIONAL ASSESSMENT; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL;

AGE FACTORS; AGED; C-REACTIVE PROTEIN; CALCIUM; CHELATING AGENTS; COHORT STUDIES; FEMALE; HUMANS; INFLAMMATION; KIDNEY FAILURE; LIPIDS; MALE; MIDDLE AGED; POLYAMINES; PROSPECTIVE STUDIES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 38348999471     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111061     Document Type: Article

References (28)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(suppl 3):S112-S119.
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143.
3. Prichard SS: Impact of dyslipidemia in endstage renal disease. J Am Soc Nephrol 2003;14:S315-S320.
4. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K: Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007;18:293-303.
5. Stenvinkel P, Alvestrand A: Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002;15:329-337.
6. Wanner C, Zimmermann J, Schwedler S, et al: Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl 2002;80:99-102.
7. Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-369.
8. Arici M, Walls J: End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 2001;59:407-414.
9. Owen WF, Lowrie EG: C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998;54:627-636.
10. van den Akker JM, Bredie SJ, Diepenveen SH, et al: Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol 2003;16:238-244.
11. Seliger SL, Weiss NS, Gillen DL, et al: HMGCoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002;61:297-304.
12. Wanner C, Krane V, Marz W, et al: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238.
13. Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997;52:10-20.
14. Nishizawa Y, Shon T, Kawagishi T, Morii H: Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. Kidney Int 1997;52(suppl 62):S90-S92.
15. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:601-617.
16. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-808.
17. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(suppl 1):S1-S266.
18. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701.
19. Chertow GM, Burke SK, Raggi P, et al: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252.
20. Chertow GM, Burke SK, Dillon MA, et al: Long-term effects of sevelamer hydrochloride on the calcium-phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999;14:2907-2914.
21. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow G, Raggi P: Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005;149:820-825.
22. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.
23. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD: Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003;42:761-773.
24. Shinaberger CS, Kilpatrick RD, Regidor DL, McAllister CJ, Greenland S, Kopple JD, Kalantar-Zadeh K: Longitudinal associations between dietary protein intake and survival in hemodialysis patients. Am J Kidney Dis 2006;48:37-49.
25. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and admin istered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-1191.
26. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-780.
27. Suki W, Zabaneh R, Cangiano J, et al: The DCOR trial? A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients (abstract THPO745). Renal Week, Philadelphia, Nov 2005.
28. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-441.